GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

telitacicept   Click here for help

GtoPdb Ligand ID: 11827

Synonyms: RC18 | Tai'ai®
Approved drug Immunopharmacology Ligand
telitacicept is an approved drug (China (2021))
Compound class: Peptide
Comment: Telitacicept (RC18) is a recombinant fusion protein that combines the ligand-binding domain of the TACI receptor and the Fc component of human IgG. It was designed to inhibit the signalling of B cell BAFF and APRIL as a mechanism to treat B cell-mediated autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) [2-5].
Classification Click here for help
Compound class Peptide
Approved drug? Yes. China NMPA (2021)
International Nonproprietary Names Click here for help
INN number INN
10932 telitacicept
Synonyms Click here for help
RC18 | Tai'ai®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 895
Other databases
GtoPdb PubChem SID 461663383
Search PubMed clinical trials telitacicept
Search PubMed titles telitacicept
Search PubMed titles/abstracts telitacicept